| Qiu, Lugui |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
NCT06319456: A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. |
|
|
| Recruiting | 3 | 344 | RoW | Lisaftoclax (APG-2575), Acalabrutinib, Fludarabine, Cyclophosphamide，CTX, Rituximab, Chlorambucil | Ascentage Pharma Group Inc. | CLL/SLL | 08/27 | 08/28 | | |
D822BC00001, NCT04075292: Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | 3 | 155 | RoW | Acalabrutinib, Rituximab, Chlorambucil | AstraZeneca | Untreated Chronic Lymphocytic Leukemia | 01/24 | 03/25 | | |
|
|
|
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT06539195: DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) |
|
|
| Recruiting | 2 | 180 | RoW | DZD8586 | Dizal Pharmaceuticals | Diffuse Large B Cell Lymphoma | 10/27 | 04/28 | | |
FUMANBA-1, NCT05066646: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 132 | RoW | CT103A | Nanjing IASO Biotherapeutics Co.,Ltd | Multiple Myeloma | 10/22 | 06/24 | | |
| Recruiting | 1/2 | 154 | RoW | MBS314 Injection | Beijing Mabworks Biotech Co., Ltd. | Relapsed or Refractory Multiple Myeloma | 02/26 | 03/28 | | |
NCT05521802: A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 92 | RoW | B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell | Cellular Biomedicine Group Ltd. | Multiple Myeloma | 07/24 | 07/37 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
| Completed | 1/2 | 15 | Europe, Canada, US, RoW | Modakafusp Alfa, TAK-573, Daratumumab | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 05/24 | 05/24 | | |
NCT05944978: A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies |
|
|
| Recruiting | 1/2 | 40 | RoW | GNC-035 | Sichuan Baili Pharmaceutical Co., Ltd. | Relapsed/Refractory Chronic Lymphocytic Leukemia | 08/25 | 08/25 | | |
| Recruiting | 1 | 58 | RoW | YY-20394 | Shanghai YingLi Pharmaceutical Co. Ltd. | Relapsed or Refractory Peripheral T-Cell Lymphoma | 06/21 | 12/21 | | |
NCT04250324: Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma |
|
|
| Recruiting | 1 | 21 | RoW | BZ019 | Shanghai Cell Therapy Group Co.,Ltd, Institute of Hematology & Blood Diseases Hospital, Tianjin Medical University Cancer Institute and Hospital | Large B-cell Lymphoma | 08/22 | 12/22 | | |
NCT05011097: A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 75 | RoW | Y150 | Wuhan YZY Biopharma Co., Ltd. | Relapsed or Refractory Multiple Myeloma | 07/23 | 12/24 | | |
NCT03664297: Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor |
|
|
| Active, not recruiting | 1 | 86 | RoW | SHR1459, No other intervention | Jiangsu HengRui Medicine Co., Ltd. | Mature B Cell Neoplasms | 12/23 | 12/24 | | |
NCT05758610: A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients |
|
|
| Recruiting | 1 | 60 | RoW | ETH-155008, Study drug | Shengke Pharmaceuticals (Jiangsu) Limited, China | NHL, Adult, AML, Adult Recurrent | 12/25 | 06/26 | | |
NCT05318963: Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma |
|
|
| Recruiting | 1 | 34 | RoW | LCAR-AIO cells product | Qiu Lugui, Nanjing Legend Biotech Co. | B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | 06/24 | 06/26 | | |
| Recruiting | 1 | 116 | RoW | TQB3820 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hematological Malignancies | 08/24 | 12/24 | | |
NCT06615193: A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor |
|
|
| Recruiting | 1 | 111 | RoW | HDM2005 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy | 06/26 | 02/28 | | |
| Recruiting | 1 | 191 | RoW | ICP-248, ICP-248+Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematological Malignancies | 08/25 | 10/26 | | |
NCT05920876: A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 100 | RoW | QLS32015, A Humanized GPRC5D x CD3 Bispecific Antibody | Qilu Pharmaceutical Co., Ltd. | Relapsed or Refractory Multiple Myeloma | 12/24 | 08/25 | | |
NCT05913804: YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma |
|
|
| Not yet recruiting | 1 | 8 | RoW | YTS104 Cells injection | Institute of Hematology & Blood Diseases Hospital, China Immunotech (Beijing) Biotechnology Co., Ltd. | Relapsed or Refractory Multiple Myeloma | 12/25 | 12/25 | | |
NCT06047197: Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 1 | 25 | RoW | RC19D2 cell injection | Beijing Yongtai Ruike Biotechnology Company Ltd | Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | 09/26 | 12/26 | | |
NCT05693012: Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma |
|
|
| Recruiting | N/A | 398 | RoW | cfDNA methylation assessment | Qiu Lugui, Guangzhou Burning Rock Dx Co., Ltd. | Multiple Myeloma | 12/23 | 12/24 | | |
| Xiao, Zhijian |
| Recruiting | 2 | 105 | RoW | TQ05105 tablets, Hydroxycarbamide tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Moderate and High Risk Myelofibrosis | 03/23 | 09/23 | | |
AK117-205, NCT06196203: A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes |
|
|
| Recruiting | 2 | 90 | US, RoW | AK117, Placebo, Azacitidine | Akeso | Higher-risk Myelodysplastic Syndromes | 01/26 | 06/26 | | |
NCT06457425: Flunotinib Maleate Phase II Intermediate-High Risk Bone Fiber Clinical Trial |
|
|
| Recruiting | 2 | 75 | RoW | Flonoltinib 50mg, Flonoltinib 100mg, Ruxolitinib | Chengdu Zenitar Biomedical Technology Co., Ltd | MF,PMF,PPV-MF,PET-MF | 05/26 | 07/26 | | |
HATCH, NCT04691141: A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) |
|
|
| Terminated | 1/2 | 15 | RoW | ATG-016 | Shanghai Antengene Corporation Limited | Myelodysplastic Syndrome | 09/23 | 09/23 | | |
| Recruiting | 1b | 32 | RoW | BC3402, Azacitidine | Biocity Biopharmaceutics Co., Ltd. | Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | 03/25 | 12/25 | | |
NCT04485065: Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS |
|
|
| Suspended | 1 | 120 | RoW | IBI188+azacitidine | Innovent Biologics (Suzhou) Co. Ltd. | Myelodysplastic Syndromes | 12/23 | 08/24 | | |
| Wang, Tingyu |
NCT05147467: Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL |
|
|
| Recruiting | 2 | 75 | RoW | APG2575 | Ascentage Pharma Group Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 09/24 | 12/24 | | |
| Not yet recruiting | 2 | 30 | RoW | R-EPOCH in Combination With Ibrutinib | Institute of Hematology & Blood Diseases Hospital, Xian-Janssen Pharmaceutical Ltd. | Richter Transformation | 08/24 | 08/25 | | |
| Jiao, Ying |
| No trials found |
